Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
This PHASE3 trial investigates COVID-19 and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
May 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — May 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE3
First recorded
May 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .